Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiomaximaWAR:BMX +4.38%51 EV-to-FCF is 124.55 as of Jul. 20, 2026, which is 26976% above its 10-year median of 0.46. GuruFocus rates WAR:BMX with a GF Score™ of 51/100 and a GF Value™ of zł15.44 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 99 Medical Diagnostics & Research companies, Biomaxima ranks worse than 90.91% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Biomaxima's Enterprise Value is zł56.67 Mil.
Biomaxima's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was zł0.46 Mil. Therefore, Biomaxima's EV-to-FCF for today is 124.55.
The historical rank and industry rank for Biomaxima's EV-to-FCF or its related term are showing as below:
WAR:BMX'
s EV-to-FCF Range Over the Past 10 Years
Min: -502.94 Med: 0.46 Max: 313.47
Current: 120.77
During the past 13 years, the highest EV-to-FCF of Biomaxima was 313.47. The lowest was -502.94. And the median was 0.46.
WAR:BMX's EV-to-FCF is ranked worse than 90.91% of 99
companies
in the Medical Diagnostics & Research industry
Industry Median: 27.8
vs WAR:BMX: 120.77
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biomaxima's share price for today is zł9.77.
Biomaxima's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-0.020.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Biomaxima EV-to-FCF Related Terms
Biomaxima EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Biomaxima's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Biomaxima's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomaxima EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biomaxima's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Biomaxima's EV-to-FCF falls into.
Biomaxima's current Enterprise Value is zł56.67 Mil.
Biomaxima's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomaxima (WAR:BMX) has a EV-to-FCF of 124.55 as of Jul. 20, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Biomaxima and its competitors. This is 26976% above median its historical median of 0.46. According to the industry distribution chart, Biomaxima ranks #90 out of 99 companies in the Medical Diagnostics & Research industry, placing it in the top 90.9%.
Is Biomaxima's EV-to-FCF too high?
Biomaxima's current EV-to-FCF of 124.55 is 26976% above median its 10-year median of 0.46. The Medical Diagnostics & Research industry median EV-to-FCF is 27.80. Biomaxima's value of 124.55 is 348% above this industry median. Based on the distribution chart, Biomaxima ranks #90 out of 99 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Biomaxima has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biomaxima's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Biomaxima ranks #90 out of 99 companies for EV-to-FCF. This places Biomaxima in the lower half of its industry. The industry median EV-to-FCF is 27.80. Biomaxima's value of 124.55 is 348% above this benchmark. While the company's 10-year median is 0.46 vs. the industry median of 27.80, Biomaxima has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 27.80, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biomaxima's current EV-to-FCF of 124.55 is 348% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Biomaxima and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 27.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomaxima's current EV-to-FCF is 124.55, which is 26976% above median its own 10-year median of 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomaxima stock overvalued right now?
Based on GuruFocus' analysis, Biomaxima (WAR:BMX) is currently considered Possible Value Trap. The stock's GF Value™ is zł15.44, compared to a current price of zł9.77 — trading 36.7% below its estimated fair value. The current EV-to-FCF is 124.55, which is 26976% above median its 10-year median of 0.46 and 348% above the Medical Diagnostics & Research industry median of 27.80. Biomaxima's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Biomaxima (WAR:BMX), the current EV-to-FCF is 124.55 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biomaxima (WAR:BMX) Overvalued in 2026?
Based on GuruFocus' analysis, Biomaxima stock appears to be undervalued.
The current stock price of zł9.77 is trading 36.7% below its estimated GF Value™ of zł15.44.
GuruFocus considers Biomaxima to be Possible Value Trap.
Key valuation signals for WAR:BMX:
EV-to-FCF: 124.55 (26976% above median its 10-year median of 0.46)
GF Value™: zł15.44 vs. price of zł9.77 (36.7% below fair value)
Industry Position: 348% above the Medical Diagnostics & Research median (#90 of 99)
No single metric tells the full story. See the WAR:BMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMaxima SA is a Polish company operating in the market of laboratory diagnostics. It is a manufacturer of microbiological substrates as well as a wide range of reagents and diagnostic equipment. The company is also a distributor of products of recognized multinational diagnostic companies such as: Accelerate Diagnostics, Nova Biomedical, PHC Group, Technoclone, Kabe and Biolog.
51GF Score
Get the complete analysis for WAR:BMX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:BMX has been successfully added to your 
